Trials / Completed
CompletedNCT03229746
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Hydroxychloroquine has been reported to have a clinically significant effect on the platelet count in systemic lupus thrombocytopenia. Its action may be due to its immune modulator effect. Immune thrombocytopenia (ITP) is known as an immune-mediated acquired disease characterized by transient or persistent decrease of the platelet count. However, refractory ITP is lacking of effective treatments and the efficacy of decitabine in ITP remains poorly understood. Data from this study may provide some idea of Hydroxychloroquine in the treatment of ITP in comparison to other lines of treatment as detected by the standardized definitions.
Detailed description
This study will include patients with chronic ITP attending the out patients clinic of Clinical Hematology Unit of Internal Medicine Department of Assiut university Hospital to evaluate the safety and efficacy of hydroxychloroquine in comparison to other lines of treatment as detected by the standardized definitions . Detect the predictors for chronic ITP especially anti-nuclear antibodies (ANA) role and the effect of the proposed drugs on the level of anti-platelet antibodies. Evaluation of the health-related quality of life after treatments to answer this question; Is the most effective drug is linked to the best quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Hydroxychloroquine | 200mg twice daily orally for at least 12 weeks |
| DRUG | vincristine | 1mg intravenous weekly for 4 weeks |
| DRUG | azathioprine | dose 100mg daily for at least 3 weeks |
Timeline
- Start date
- 2017-08-01
- Primary completion
- 2018-06-01
- Completion
- 2018-06-01
- First posted
- 2017-07-26
- Last updated
- 2018-06-28
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03229746. Inclusion in this directory is not an endorsement.